Signaturefd LLC Has $94,000 Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Signaturefd LLC decreased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 15.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,680 shares of the biotechnology company’s stock after selling 823 shares during the period. Signaturefd LLC’s holdings in ADMA Biologics were worth $94,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in ADMA. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of ADMA Biologics in the first quarter valued at about $17,221,000. Bank of Montreal Can acquired a new stake in ADMA Biologics during the second quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. grew its stake in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after purchasing an additional 1,442,799 shares during the period. Castleark Management LLC acquired a new stake in ADMA Biologics during the first quarter worth approximately $5,400,000. Finally, Hillsdale Investment Management Inc. grew its stake in ADMA Biologics by 41,893.3% in the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock valued at $4,157,000 after acquiring an additional 628,400 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insiders Place Their Bets

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock valued at $8,224,121 over the last 90 days. Insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $16.43 on Tuesday. The stock has a market cap of $3.81 billion, a PE ratio of -821.50 and a beta of 0.62. ADMA Biologics, Inc. has a fifty-two week low of $3.23 and a fifty-two week high of $21.13. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The stock has a fifty day moving average of $17.93 and a 200-day moving average of $13.07.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same period in the previous year, the business earned ($0.02) earnings per share. The firm’s quarterly revenue was up 78.4% compared to the same quarter last year. Equities research analysts anticipate that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on ADMA shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of ADMA Biologics in a research note on Monday, October 14th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.